Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
22 janv. 2025 09h00 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have...
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
31 déc. 2024 09h00 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA deliveryCircular mRNA significantly increasing protein expression...
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
20 déc. 2024 08h00 HE
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No reverse stock split planned Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:...
Altamira Therapeutics Provides Update on Nasdaq Listing
04 oct. 2024 16h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the...
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
20 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
19 sept. 2024 16h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
17 sept. 2024 17h00 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
06 juil. 2021 09h00 HE
|
Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
21 juin 2021 08h30 HE
|
Auris Medical AG
Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of...